Toronto Dominion Bank Has $42.74 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Toronto Dominion Bank grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,005 shares of the biopharmaceutical company's stock after purchasing an additional 5,286 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Regeneron Pharmaceuticals worth $42,743,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Pamalican Asset Management Ltd bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $356,000. Rhenman & Partners Asset Management AB lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the last quarter. Fagan Associates Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the last quarter. Finally, Golden State Equity Partners grew its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after acquiring an additional 1,272 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 1.7%

REGN traded down $10.17 during midday trading on Wednesday, hitting $604.62. 1,089,118 shares of the company's stock traded hands, compared to its average volume of 795,612. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $65.28 billion, a PE ratio of 15.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20. The stock's fifty day simple moving average is $596.79 and its 200-day simple moving average is $679.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the business posted $9.55 EPS. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REGN. Guggenheim reduced their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the stock from $600.00 to $700.00 in a report on Wednesday, May 14th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Finally, Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.